ScreenerHero

AVBPArriVent BioPharma Inc. Common Stock

NAS · US · Healthcare · Biotechnology · arrivent.com
29.12USD-3.00%Mkt Cap: 1.44B $P/E: —

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lea…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.44B $
Enterprise Value1.07B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-166.31M $
Revenue/Share—
Last Price29.12 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees77
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.67
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.84
EPS (TTM)-3.46
EPS (Forward)-3.81
52W Range
17.0064% of range35.83
52W High35.83 USD
52W Low17.00 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.13%
ROA-49.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-160.59M $
CapEx (TTM)—
FCF Margin—
FCF Yield-6.23%
Net Debt-372.77M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio14.16
Quick Ratio13.40
Book Value/Sh7.592 USD
Cash/Share7.567 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)44.70 USD
Upside (mean)+53.5%
Target Range40.00 USD – 50.00 USD
$40.00+53.5% to mean$50.00
# Analysts10
Ownership
Shares Out.49.31M
Float32.11M
Insiders1.54%
Institutions98.67%
Short Interest
Short Ratio15.4d
Short % Float18.39%
Short % Out.17.28%
Shares Short8.05M
Short (prev mo.)7.62M
Technical
SMA 5031.60 (-7.9%)
SMA 20026.10 (+11.6%)
Beta1.37
S&P 52W Chg18.16%
Avg Vol (30d)451.32K
Avg Vol (10d)423.41K
Technical Indicators
RSI (14)41.7
MACD-0.4921
MACD Signal-0.3710
MACD Hist.-0.1211
BB Upper32.12 USD
BB Middle30.45 USD
BB Lower28.78 USD
BB Width10.98%
ATR (14)1.570 USD
Vol Ratio (20d)0.70x